Pompe Disease: Current State and Future Treatments.

Area of Science:

• Genetics
• Molecular Biology
• Biochemistry

Background:

• Pompe disease is an autosomal recessive genetic disorder caused by mutations in the acid α-glucosidase (GAA) gene, leading to glycogen accumulation in lysosomes.
• While enzyme replacement therapy (ERT) improves outcomes, it has limitations, and patient quality of life remains low.
• Emerging research highlights the role of autophagy in Pompe disease pathology.

Purpose of the Study:

• To review the current understanding of Pompe disease, including its genetic basis and pathological mechanisms.
• To evaluate the efficacy and safety of enzyme replacement therapy (ERT) as the standard of care.
• To explore the potential of novel gene therapy approaches, specifically adeno-associated virus-mediated (AAV) gene therapy, for Pompe disease.

Main Methods:

• Review of existing literature on Pompe disease, enzyme replacement therapy, and gene therapy.
• Analysis of data from preclinical studies and early-phase clinical trials (Phase I/II) of AAV-mediated gene therapy (rAAV1-hGAA).
• Assessment of safety profiles, including common side effects associated with gene therapy procedures.

Main Results:

• Enzyme replacement therapy (ERT) has demonstrated benefits in survival and functional tests for Pompe disease patients.
• Gene therapy using rAAV1-hGAA has shown promising safety in Phase I/II trials, with sustained GAA levels and some pulmonary function improvements.
• Despite ERT advancements, significant challenges remain in improving long-term quality of life and life expectancy for Pompe disease patients.

Conclusions:

• Gene therapy represents a potential long-term treatment strategy for Pompe disease, offering an alternative to current ERT.
• Ongoing clinical trials are crucial for further evaluating the safety and efficacy of gene therapy in Pompe disease.
• Further research into Pompe disease mechanisms, including autophagy, may reveal new therapeutic targets.